A Study to Evaluate ALN-4285 in Adult Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-4285 in Adult Healthy Volunteers

The purpose of this study is to:

• evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers
• characterize the single-dose pharmacokinetics (PK) of ALN-4285

Inclusion Criteria:

• Has a body mass index (BMI) of ≥18.0 kg/m^2 and ≤30 kg/m^2
• Has 12-lead ECG within normal limits or with no clinically significant abnormalities in the opinion of the Investigator

Exclusion Criteria:

• Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >upper limit of normal (ULN)
• Has total bilirubin >ULN
• Has systolic blood pressure >140 mmHg and/or a diastolic blood pressure >90 mmHg
• Has an estimated glomerular filtration (eGFR) of <90 mL/min/1.73m^2 at screening
• Has received an investigational agent within the last 30 days or 5 half-lives